{"id":729127,"date":"2023-02-07T07:03:24","date_gmt":"2023-02-07T12:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-07T07:03:24","modified_gmt":"2023-02-07T12:03:24","slug":"enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/","title":{"rendered":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference"},"content":{"rendered":"

<\/p>\n

Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference<\/b><\/p>\n

WATERTOWN, Mass.–(BUSINESS WIRE<\/a>)–
\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET.\n<\/p>\n

\nA live webcast of the event will be accessible by visiting the \u201cEvents and Presentations\u201d section on the \u201cInvestors\u201d page of Enanta\u2019s website at www.enanta.com<\/a>. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.\n<\/p>\n

About Enanta Pharmaceuticals, Inc.
\n
<\/b>Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta\u2019s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).\n<\/p>\n

\nEnanta\u2019s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). Please visit www.enanta.com<\/a> for more information.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230207005136\/en\/<\/a><\/span><\/p>\n

Media and Investor Contact:
\n<\/b>
Jennifer Viera
\n
617-744-3848
\n
jviera@enanta.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Health COVID-19 Infectious Diseases Other Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET. A live webcast of the event will be accessible by visiting the \u201cEvents and Presentations\u201d section on the \u201cInvestors\u201d page of Enanta\u2019s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and … <\/p>\n

Continue reading “Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-729127","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET. A live webcast of the event will be accessible by visiting the \u201cEvents and Presentations\u201d section on the \u201cInvestors\u201d page of Enanta\u2019s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and … Continue reading "Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-07T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-02-07T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":314,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/\",\"name\":\"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-02-07T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk","og_description":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET. A live webcast of the event will be accessible by visiting the \u201cEvents and Presentations\u201d section on the \u201cInvestors\u201d page of Enanta\u2019s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and … Continue reading \"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-07T12:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference","datePublished":"2023-02-07T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/"},"wordCount":314,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/","name":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-02-07T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230207005136r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/729127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=729127"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/729127\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=729127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=729127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=729127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}